A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (381 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerhigh riskchemotherapyleukemiatumor
  Phrases that lowered it: kgmyelomamass indexbody massallergy
• Accepts healthy volunteers: No (raises risk) · Who can join
• Primary purpose: prevention (lowers risk) · Design
• Drug's FAERS reports with a death: 27.9% (raises risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Sponsor's past termination rate: 8.8% (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 97.2% (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 35 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 3 (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Disease area, respiratory: Yes (raises risk) · Disease area
• Collaborators: 2 (lowers risk) · Design
• Sponsor's past trials: 57 (raises risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism NCT03297359 · started 2018 · scored riskier than 81% of active trials terminated
• Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients NCT02048865 · started 2014 · scored riskier than 90% of active trials completed
• A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE NCT05171075 · started 2022 · scored riskier than 55% of active trials terminated
• Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery NCT01061411 · started 2010 · scored riskier than 77% of active trials completed
• Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients NCT02706249 · started 2016 · scored riskier than 85% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.